ABBVIE (ABBV) Earnings Date & Reports

Key Takeaways

• AbbVie reported second-quarter 2026 net revenues of $16.99 billion, up 10.2% year over year and ahead of Wall Street expectations.
• Adjusted diluted earnings per share (EPS) came in at $3.65, beating guidance and the consensus estimate of $3.61.
• Growth franchises Skyrizi (up 24%) and Rinvoq (up 23.7%) again led results, offsetting the continued decline of legacy blockbuster Humira.
• AbbVie raised its full-year revenue outlook by $300 million to about $67.6 billion, while trimming adjusted EPS guidance to $13.87–$14.07 to reflect the planned Apogee Therapeutics acquisition.
• Shares slipped roughly 2.5% on the report, as investors weighed the stronger revenue outlook against acquisition-related earnings dilution.

Earnings Context and Why It Matters

AbbVie's second-quarter report is a key test of the company's post-Humira strategy. Humira, once its largest drug, continues to lose sales to biosimilar competition, so investors are focused on whether newer immunology medicines Skyrizi and Rinvoq can keep replacing that revenue. This quarter showed they are delivering, with both growing more than 20% and the neuroscience portfolio adding roughly 20% growth as well. The results also carry a strategic dimension: management announced the acquisition of Apogee Therapeutics, a move aimed at extending its immunology pipeline into the 2030s. For investors, this report clarifies both near-term momentum and the cost of that long-term growth.

Reported Results

AbbVie posted second-quarter 2026 net revenues of $16.99 billion, an increase of 10.2% versus the prior year and above the consensus estimate of roughly $16.8 billion. On a generally accepted accounting principles (GAAP) basis, diluted EPS was $2.03. Adjusted diluted EPS, which excludes specified items, was $3.65, an increase of 22.9% and about $0.04 above consensus. Management noted these results included an unfavorable impact of $0.17 per share from acquired in-process research and development (IPR&D) and milestone expenses.

The immunology franchise delivered nearly $8.8 billion in revenue, up 14.6% on an operational basis. Skyrizi generated $5.5 billion (up 24%) and Rinvoq more than $2.5 billion (up 23.7%), while Humira fell 36.1% to about $706 million amid biosimilar pressure. Neuroscience revenue topped $3.2 billion, up about 20%, though oncology slipped 2.4% and aesthetics declined modestly.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves in names like AbbVie, the AI Screener offers a practical way to identify related setups and monitor shifting market conditions.

Market Reaction and Investor Sentiment

The market's response to AbbVie's results was mixed. Despite a revenue and earnings beat, shares fell about 2.5% to $245.10 on July 31, 2026, and continued to drift lower in the following days. The decline reflected investor focus on guidance rather than the headline numbers. While AbbVie raised its full-year revenue outlook by $300 million to approximately $67.6 billion, it simultaneously lowered its 2026 adjusted EPS range to $13.87–$14.07 from $13.91–$14.11, largely due to an expected $0.14 per-share dilution from the Apogee Therapeutics acquisition. Sentiment remains generally constructive on the company's core growth drugs, but the earnings adjustment and ongoing questions around competitive pressure in psoriasis and the aesthetics market kept enthusiasm in check.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several themes. First is the integration of Apogee Therapeutics, whose $10.9 billion acquisition is expected to close in the third quarter of 2026 and adds roughly $0.14 of near-term earnings dilution. Management expects the deal to bolster its immunology pipeline with long-acting biologics targeting dermatology and respiratory conditions.

Second, Skyrizi and Rinvoq remain the core growth story. AbbVie raised its full-year Skyrizi outlook to about $21.7 billion and highlighted potential U.S. approvals for Rinvoq in vitiligo and alopecia areata, indications management now believes could approach $2 billion in combined peak sales. A subcutaneous induction option for Skyrizi in Crohn's disease is also under review, with a potential approval later this fall.

Third, watch for continued pressure in legacy and challenged franchises. Humira is still declining in line with expectations, oncology faces headwinds from Imbruvica, and aesthetics remains soft. For the third quarter, AbbVie guided to roughly $17.2 billion in revenue and adjusted EPS of $3.84 to $3.88. How these segments perform, alongside the closing and early impact of the Apogee deal, will shape the next leg of the story.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations